Skip to main content

Table 3 Baseline information of NSCLC patients with EGFR mutation

From: Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology

Clinical factors

Patients (%)

Death

Log-rank test, p

Age

  > =65

24 (53.3%)

14

0.70

  < 65

21 (46.7%)

9

 

Gender

 Male

13 (28.9%)

7

0.6

 Female

32 (71.1%)

16

 

Race

 Asian

2 (4.4%)

1

0.6

 Black or African American

3 (6.7%)

1

 

 Not reported

4 (8.9%)

1

 

 White

36 (80.0%)

20

 

Cancer Status

 Tumor free

20 (44.4%)

6

0.01*

 With tumor

15 (33.3%)

12

 

 Unknow

10 (22.2)

5

 

Stage

 Stage I

22 (48.9%)

9

0.6

 Stage II

9 (20.0%)

5

 

 Stage III

11 (24.4%)

8

 

 Stage IV

2 (4.4%)

1

 

 Not reported

1 (2.2%)

0